Pfizer's third-generation ALK inhibitor lorlatinib approved in China for the treatment of non-small cell lung cancer

On April 29, the NMPA official website announced that Pfizer’s lorlatinib tablets have been approved in China for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)

Lorlatinib is a third-generation ALK inhibitor that has shown high activity in preclinical lung cancer models harboring ALK rearrangements

In April 2017, Lorlatinib was granted Breakthrough Drug Designation by the FDA for ALK-positive, metastatic NSCLC that has previously received one or more ALK inhibitors and has progressed after treatment

In October 2017, Pfizer announced the complete data of the phase II clinical trial of Lorlatinib, which showed that the drug showed clinically meaningful activity in the treatment of lung tumors and brain metastases in patients with ALK-positive and ROS1-positive advanced NSCLC

In April, Pfizer also announced the latest results of the Phase 3 CROWN trial at the 2022 AACR Annual Meeting

Lung cancer is the leading cause of death from cancer worldwide, and NSCLC accounts for approximately 80-85% of lung cancers